NRX Pharmaceuticals (STU:B1Q) Additional Paid-In Capital : €225.03 Mil(As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Additional Paid-In Capital?

NRX Pharmaceuticals's quarterly additional paid-in capital declined from Sep. 2023 (€227.25 Mil) to Dec. 2023 (€221.30 Mil) but then increased from Dec. 2023 (€221.30 Mil) to Mar. 2024 (€225.03 Mil).

NRX Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (€180.53 Mil) to Dec. 2022 (€217.44 Mil) and increased from Dec. 2022 (€217.44 Mil) to Dec. 2023 (€221.30 Mil).

NRX Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for NRX Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Additional Paid-In Capital Chart

NRX Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

38.11

180.53

217.44

221.30

NRX Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial											218.16	221.42	227.25	221.30	225.03

NRX Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

NRX Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals (STU:B1Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

NRXP:USA

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines